Lung cancer trials in Germany

In Germany 182 Also abroad 2744

182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

No phaseNot yet taking people in Germany
Impact of a Reminder App on Physical Activity During Radiation Therapy for Lung Cancer
Where
Hanover, Kiel, Lübeck
Age
18 years and over
People
32 worldwide
Run by
University Hospital Schleswig-Holstein
See details and how to joinNCT07627022
Phase 2Taking people
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Where
Munich
Age
18 years and over
People
44 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT05718323 · EU 2022-502092-33-00
Phase 1/2Taking people
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Where
Dresden, Heidelberg
Age
12 years and over
People
500 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00
Phase 3Taking people
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Where
Berlin, Giessen, Heidelberg, Munich, Oldenburg
Age
18 years and over
People
180 worldwide
Run by
Nuvation Bio Inc.
See details and how to joinNCT07154706 · EU 2025-521971-29-00
Phase 1Taking people
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
Where
Cologne, Essen, Munich, Rostock
Age
18 years and over
People
76 worldwide
Run by
Novartis Pharma AG
See details and how to join2023-510356-23-00
No phaseTaking people
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
Where
Frankfurt am Main
Age
18 years and over
People
240 worldwide
Run by
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT07510724
Phase 2Taking people
Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)
Where
Berlin, Cologne, Dresden, Duesseldorf, Esslingen am Neckar, Frankfurt am Main, Frankfurt Am Main, Georgsmarienhuette, Giessen, Goettingen, Grosshansdorf, Hemer, Kiel, Mannheim, Munich, Offenbach Am Main, Oldenburg, Tuebingen
Age
18 years and over
People
40
Run by
Universitat Heidelberg
See details and how to join2024-516790-78-00
No phaseTaking people
The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
Where
Heidelberg
Age
18 years and over
People
190
Run by
University Hospital Heidelberg
See details and how to joinNCT05378633
No phaseTaking people
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Where
Tübingen
Age
18 years and over
People
8,000 worldwide
Run by
UMC Utrecht
See details and how to joinNCT04075305
Phase 2Taking people
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Where
Bonn, Freiburg im Breisgau, Giessen, Leipzig, Minden, Stuttgart, Troisdorf
Age
18 years to 74 years
People
176
Run by
University Hospital, Bonn
See details and how to joinNCT06810609 · EU 2024-516367-80-00
No phaseTaking people
Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
Where
Frankfurt
Age
18 years and over
People
45
Run by
Goethe University
See details and how to joinNCT07161310
No phaseTaking people
Risk Factors for Neuroendocrine Neoplasms
Where
Nuremberg
People
14,250
Run by
Bavarian Cancer Registry
See details and how to joinNCT06282016
Phase 2Taking people
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Where
Bonn, Dresden, Freiburg im Breisgau, Goettingen, Homburg, Moenchengladbach, Munich, Stuttgart, Troisdorf
Age
18 years and over
People
110 worldwide
Run by
TheraOp
See details and how to joinNCT06102057 · EU 2023-510506-41-00
No phaseNot yet taking people in Germany
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
Where
Heidelberg
Age
18 years and over
People
600 worldwide
Run by
OncoHost Ltd.
See details and how to joinNCT07246759
No phaseNot yet taking people in Germany
Immune-Marker Platform for Patients With Advanced Lung Cancer
Where
Cologne, Dresden
Age
18 years and over
People
500
Run by
Technische Universität Dresden
See details and how to joinNCT07150598
Phase 2Taking people
Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
Where
Essen, Heidelberg
Age
18 years and over
People
20 worldwide
Run by
University Hospital, Essen
See details and how to joinNCT06784791 · EU 2023-505662-28-00
Phase 1/2Taking people
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Where
Cologne, Dresden
Age
18 years and over
People
140 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06669117 · EU 2024-512760-64-00
No phaseNot yet taking people in Germany
Radiation-induced Toxicity of the Heart
Where
Dresden
Age
18 years and over
People
325
Run by
Technische Universität Dresden
See details and how to joinNCT06986291
Phase 2Enrolling by invitation
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Where
Berlin, Cologne, Heidelberg, Hemer, Oldenburg
Age
18 years to 120 years
People
29
Run by
University of Cologne
See details and how to joinNCT06419179 · EU 2024-512373-27-00
No phaseTaking people
Predicting Cancer Risk With Digital and Molecular Markers
Where
Please Refer to Project Homepage For Details (see Link Below)
Age
18 years and over
People
1,250
Run by
University of Erlangen-Nürnberg Medical School
See details and how to joinNCT06962670
No phaseTaking people
Giessen Pulmonary Hypertension in Lung Cancer Registry
Where
Giessen
Age
18 years and over
People
500
Run by
University of Giessen
See details and how to joinNCT04467333
No phaseTaking people
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Where
Großhansdorf
Age
18 years and over
People
248 worldwide
Run by
University Medical Center Groningen
See details and how to joinNCT06111807
Phase 2Taking people
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
Where
Berlin, Cologne, Dresden, Essen, Frankfurt, Gauting, Georgsmarienhütte, Göttingen, Halle, Hamburg, Heidelberg, Hemer, Mainz, München, Nuremberg, Oldenburg
Age
18 years and over
People
50
Run by
Goethe University
See details and how to joinNCT05281406
No phaseTaking people
Improvement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer
Where
Bamberg, Bayreuth, Coburg, Donaustauf, Kulmbach, Regensburg, Straubing
Age
18 years and over
People
220
Run by
University of Bayreuth
See details and how to joinNCT06252233
Phase 2Taking people
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Where
Heidelberg
Age
18 years and over
People
20
Run by
University Hospital Heidelberg
See details and how to joinNCT04865250